The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 985-995

  Papadopoulos, Nickolas ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DRUG THERAPY; GENES; MUTAGENESIS; PATIENT MONITORING; TUMORS;

CANCER PATIENTS; DRUG DISCOVERY; MUTATION; NORMAL CELLS;

PROGRAM DIAGNOSTICS;

ALPHA INTERFERON; ANTIINFECTIVE AGENT; BEVACIZUMAB; CAMPTOSTAR; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GAMZAR; GEFITINIB; GEMCITABINE; HYDROXYUREA; IMATINIB; IRINOTECAN; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; FISH; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

GENE TARGETING; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS;

EID: 33747050886     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1234     Document Type: Review

References (91)

1. Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
2. O'Brien, S.G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003).
3. Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464 (2003).
4. Hughes, T.P. et al. for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
5. Druker, B.J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001). (Published erratum appears in N. Engl. J. Med. 345, 232 (2001).)
6. Kantarjian, H. et al. for the international ST571 CML study group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
7. Talpaz, M. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928-1937 (2002).
8. Sawyers, C.L. et al. Imatinib induce hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539 (2002).
9. Kantarjian, H.M. et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99, 3547-3553 (2002).
10. Ottmann, O.G. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100, 1965-1971 (2002).
11. Gabert, J. et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 17, 2318-2357 (2003).
12. Rosti, G. et al. for the Study and Writing Committee of the Italian Cooperative Study Group (ICSG) on Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 103, 2284-2290 (2004).
13. Martinelli, G. et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann. Oncol. 17, 495-502 (2006).
14. Wang, L., Knight, K., Lucas, C. & Clark, R.E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 91, 235-239 (2006).
15. Kang, H.Y. et al. Comparison of allele specific oligonucleotide- polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatininb. Haematologica 91, 659-662 (2006).
16. Iacobucci, I. et al. Comparison between patients with philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J. Clin. Oncol. 24, 454-459 (2006).
17. Yanada, M. et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A Phase II Study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24, 460-466 (2006).
18. Rea, D. et al. on behalf of the Intergroupe Français des Leucémies Myéloïdes CHronique (FI φLMC) and of the Group for Research in Adult Lymphoblastic Leukemia (GRAALL). High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20, 400-403 (2006).
19. Wassmann, B. et al. Alternative versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood, advance online publication 25 April 2006 (doi 10.1182/blood-2005-11-4386).
20. Demetri, G.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
21. van Oosterom, A.T. et al. European organisation for research and treatment of cancer soft tissue and bone sarcoma group. safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423 (2001).
22. Diebiec-Rychter, M. et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 40, 689-695 (2004).
23. Singer, S. et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol. 20, 3898-3905 (2002).
24. Barthe, C., Cony-Makhoul, P., Melo, J.V. & Mahon, J.R. Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163 (2001).
25. Hofmann, W.K. et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99, 1860-1862 (2002).
26. von Bubnoff, N., Schneller, F., Peschel, C. & Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome- positive leukaemia to STI571: a prospective study. Lancet 359, 487-491 (2002).
27. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
28. Shah, N.P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
29. Hochhaus, A. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196 (2002).
30. Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
31. Burgess, M.R., Skaggs, B.J., Shah, N.P., Lee, F.Y. & Sawyers, C.L. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. USA 102, 3395-3400 (2005).
32. Lomabardo, L.J. et al. Discovery of N-(2-chloro-6-methyl-phanul)-2-(6-(4- (2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004).
33. Weisberg, E. et al. Characterization of AMN107, a selective inhbitor of native and mutant Bcr-Abl. Cancer Cell 7, 129-141 (2005).
34. Komarova, N.L. & Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 102, 9714-9719 (2005).
35. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 102, 16368-16373 (2005).
36. Margulies, M. et al. Genome sequencing in microfabricated high-density picolitre reactions. Nature 437, 376-380 (2005). (Published corrigendum appears in Nature 441, 120 (2006).)
37. Shendure, J. et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309, 1728-1732 (2005).
38. Li, M., Diehl, F., Dressman, D., Vogelstein, B. & Kinzler, K. BEAMing up for detection and quandification or rare sequence variants. Nat. Methods 3, 95-97 (2006).
39. Torsen, T., Maerkl, S.J. & Quake, S.R. Microfluidic large-scale integration. Science 298, 580-584 (2002).
40. Slamon, D.J. et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial. N. Engl. J. Med. 344, 783-792 (2001).
41. Piccart-Gebhart, M.J. et al. for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
42. Romond, H.E. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
43. Papaldo, P. et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann. Oncol. 17, 630-636 (2006).
44. Joensuu, H. et al. The FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
45. Tubbs, R.R. et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J. Clin. Oncol. 19, 2714-2721 (2001).
46. Press, M.F. et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J. Clin. Oncol. 20, 3095-3105 (2002).
47. Willmore, C., Holden, J.A. & Layfield, L.J. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. Appl. Immunohistochem. Mol. Morphol. 13, 333-341 (2005).
48. Hicks, D.G. & Tubbs, R.R. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36, 250-261 (2005).
49. Isola, J. et al. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 10, 4793-4798 (2004).
50. Hanna, W.M. & Kwok, K. Chromogenic in-situ hybridization: a viable alterative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod. Pathol. 19, 481-487 (2006).
51. Tangrea, M.A. et al. Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn. Mol. Pathol. 13, 207-212 (2004).
52. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
53. Saltz, L.B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
54. Vincenzi, B., Santini, D. & Tonini, G. Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. Ann. Oncol. 17, 527-528 (2006).
55. Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286 (2005).
56. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colortectal cancer. Cancer Res. 66, 3992-3995 (2006).
57. Bonner, J.A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006).
58. Barber, T.D., Vogelstein, B., Kinzler, K.W. & Velculescu, V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004).
59. Gopal, A.K. & Press, O.W. Clinical applications of anti-CD20 antibodies. J. Lab. Clin. Med. 134, 445-450 (1999).
60. Jain, R.K., Duda, D.G., Clark, J.W. & Loeffler, J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24-40 (2006).
61. Kris, M.G. et al. Efficacy of gefitinib, an ihibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 290, 2129-2158 (2003).
62. Fukuoka, M., Kris, M.G., Baselga, J., Ochs, J.S. & Haber, D.A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081-8092 (2005).
63. Shepherd, F.A. et al. The National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
64. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
65. Paez, J.G. et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
66. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
67. Motzer, R.J., Hoosen, S., Bell, C.L. & Christensen, J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs 15, 553-561 (2006).
68. Schõffski, P. et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Annals of Oncology, published online 17 January 2006 (doi:10.1093/annonc/mdj133).
69. Torrance, C.J., Agrawal, V., Vogelstein, B. & Kinzler, K.W. Use of isogenic cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19, 940-945 (2001).
70. Weinstein, I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64 (2002).
71. Robert, F. et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 9089-9096 (2006).
72. Thienelt, C.D. et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 22, 8786-8793 (2005).
73. Huang, S-F. et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195-8203 (2004).
74. Han, S-W. et al. Predicitve and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 11, 2493-2501 (2005).
75. Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520 (2005).
76. Kim, K-S. et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 11, 2244-2251 (2005).
77. Tokumo, M. et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167-1173 (2005).
78. Chou, T-Y. et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750-3757 (2005).
79. Mu, X.L. et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer Res. 11, 4289-4294 (2005).
80. Cortes-Funes, H. et al. On behalf of the Spanish Lung Cancer Group. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081-1086 (2005).
81. Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. National Can. Inst. 97, 643-655 (2005).
82. Takano, T. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829-6837 (2005).
83. Bell, D.W. et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib Trials. J. Clin. Oncol. 23, 8081-8092 (2005).
84. Reily, G.J. et al. Clinical course of patients with non-small cell lung cacner and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839-844 (2006).
85. Fujiwara, Y. et al. Relationship between epidermal growth factor receptor mutations and the severity of adverse events by gefetinib in patients with advanced non-small cell lung cancer. Lung Cancer 52, 99-103 (2006).
86. Shimato, S. et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefetinib. Neuro-oncol. 8, 137-144 (2006).
87. Han, S-W. et al. Optimization of patient selection for gefetinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. 12, 2538-2544 (2006).
88. Tsao, M-S. et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144 (2005).
89. Eberhard, D.A. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909 (2005).
90. Nahta, R. et al. Herceptin: mechanisms of action and resistance. Can. Lett. 232, 123-128 (2006).
91. Hynes, N.E. & Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Can. 5, 341-354 (2005).